Liddle Alexander D, Rodríguez-Merchán E Carlos
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Department of Orthopaedic Surgery, La Paz University Hospital, Madrid, Spain
Am J Sports Med. 2015 Oct;43(10):2583-90. doi: 10.1177/0363546514560726. Epub 2014 Dec 18.
Patellar tendinopathy (PT) is a major cause of morbidity in both high-level and recreational athletes. While there is good evidence for the effectiveness of eccentric exercise regimens in its treatment, a large proportion of patients have disease that is refractory to such treatments. This has led to the development of novel techniques, including platelet-rich plasma (PRP) injection, which aims to stimulate a normal healing response within the abnormal patellar tendon. However, little evidence exists at present to support its use.
To determine the safety and effectiveness of PRP in the treatment of PT and to quantify its effectiveness relative to other therapies for PT.
Systematic review.
A systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A literature review was conducted of the Medline, EMBASE, and Cochrane databases as well as trial registries. Both single-arm and comparative studies were included. The outcomes of interest were pain (as measured by visual analog or other, comparable scoring systems), functional scores, and return to sport. Study quality and risk of bias were assessed using the methodological index for nonrandomized studies (MINORS) score and the Cochrane risk of bias tool.
Eleven studies fit the inclusion criteria. Of these, 2 were randomized, controlled trials (RCTs), and 1 was a prospective, nonrandomized cohort study. The remainder were single-arm case series. All noncomparative studies demonstrated a significant improvement in pain and function after PRP injection. Complications and adverse outcomes were rare. The results of the comparative studies were inconsistent, and superiority of PRP over control treatments could not be conclusively demonstrated.
Platelet-rich plasma is a safe and promising therapy in the treatment of recalcitrant PT. However, its superiority over other treatments such as physical therapy remains unproven. Further RCTs are required to determine the relative effectiveness of the many available treatments for PT and to determine the subgroups of patients who stand to gain the most from the use of these therapies.
髌腱病(PT)是高水平运动员和业余运动员发病的主要原因。虽然有充分证据表明离心运动方案对其治疗有效,但很大一部分患者的疾病对这种治疗难治。这导致了新技术的发展,包括富血小板血浆(PRP)注射,其目的是在异常髌腱内刺激正常的愈合反应。然而,目前几乎没有证据支持其使用。
确定PRP治疗PT的安全性和有效性,并量化其相对于PT其他疗法的有效性。
系统评价。
根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行系统评价。对Medline、EMBASE和Cochrane数据库以及试验注册库进行文献综述。纳入单臂研究和比较研究。感兴趣的结果是疼痛(通过视觉模拟或其他可比评分系统测量)、功能评分和恢复运动情况。使用非随机研究方法学指数(MINORS)评分和Cochrane偏倚风险工具评估研究质量和偏倚风险。
11项研究符合纳入标准。其中,2项为随机对照试验(RCT),1项为前瞻性非随机队列研究。其余为单臂病例系列。所有非比较性研究均表明PRP注射后疼痛和功能有显著改善。并发症和不良后果很少见。比较研究的结果不一致,无法确凿证明PRP优于对照治疗。
富血小板血浆是治疗难治性PT的一种安全且有前景的疗法。然而,其相对于物理治疗等其他治疗的优越性尚未得到证实。需要进一步的RCT来确定PT多种可用治疗方法的相对有效性,并确定从使用这些疗法中获益最大的患者亚组。